This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Esophagus - Cancer

July 14, 2015
This small randomized trial evaluated the potential benefits of ghrelin, an anti-inflammatory agent, in reducing the SIRS response after esophagectomy.  The ghrelin group had a reduced SIRS duration, lower CRP levels, and lower IL-6 levels compared to controls.  Pulmonary complications were reduced in the ghrelin group, but other complication inciden
June 12, 2015
Outcomes of esophagectomy, including in-hospital mortality and length of stay (LOS), were compared between England (centralized care) and the US (no centralized care).  Data for 2005-2010 included 7433 esophagectomies performed in 66 hospitals in England and 5858 esophagectomies performed in 775 hospitals in the US.  Morality was greater in the US (5
June 11, 2015
This single institution retrospective analysis of esophagectomy or gastrectomy for GEJ cancer compared outcomes between groups who did and did not complete recommended 2 cycles of postoperative adjuvant chemotherapy.  Of 110 pts who underwent perioperative chemotherapy, 67% completed postoperative adjuvant chemotherapy.  Completion of 2 cycles or mor
May 17, 2015
In this population-based cohort study with 1044 patients who underwent esophagectomy for esophageal cancer between 1987 and 2010 in Sweden, the researchers found that a higher number of lymph nodes removed did not affect mortality in any specific stage.
February 13, 2015
This carefully prepared book is a wonderful compendium of scientific evidence regarding squamous cell cancer of the esophagus, written from a Japanese perspective.
January 10, 2015
The authors retrospectively analyzed pathologic response rates and their relation to the interval between completion of induction therapy and esophagectomy for esophageal cancer in 88 patients.  Complete response rates increased from 12.5% to 40.9% among quartiles as the interval increased from <45 days to >63 days.  There was no increase in mo
November 20, 2014
Data from 20 observational studies including nearly 3000 pts were reviewed to assess the prevalence of pre-frailty/frailty and clinical outcomes in older cancer patients.  Frailty was identified in 42% and pre-frailty in 43% of patients.  Combined frailty was associated with increased all cause mortality (5-yr HR 1.57), postoperative mortality, and p
November 16, 2014
This retrospective study evaluated results of transthoracic (TTE) vs transhiatal (THE) esophagectomy in patients with squamous cell cancer and adenocarcinoma from two high volume centers.
November 11, 2014
This study explored financial conflicts of interest (FCOI) among authors of published guidelines and consensus statements and their relationship to endorsement of specific drugs.  93% of recent articles reported FCOI status.  Of articles publishing funding sources, 65% reported partial or full industry funding.  Endorsement of chemotherapeutic agents
October 8, 2014
This multicenter prospective trial evaluated the impact of induction therapy on anastomotic leak (AL) and other complications after esophagectomy.  Of 2944 included pts, 593 had induction chemoradiotherapy.  AL occurred in 8.8% of induction therapy pts compared to 10.6% of surgery only patients.  90 day postoperative morbidity and mortality rates wer